These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36866391)

  • 1. Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice.
    Seedorf K; Weber C; Vinson C; Berger S; Vuillard LM; Kiss A; Creusot S; Broux O; Geant A; Ilic C; Lemaitre K; Richard J; Hammoutene A; Mahieux J; Martiny V; Durand D; Melchiore F; Nyerges M; Paradis V; Provost N; Duvivier V; Delerive P
    JHEP Rep; 2023 Apr; 5(4):100651. PubMed ID: 36866391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease.
    Hammoutene A; Laouirem S; Albuquerque M; Colnot N; Brzustowski A; Valla D; Provost N; Delerive P; Paradis V;
    JHEP Rep; 2023 Oct; 5(10):100845. PubMed ID: 37663119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
    Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
    J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
    Shimozono R; Asaoka Y; Yoshizawa Y; Aoki T; Noda H; Yamada M; Kaino M; Mochizuki H
    Mol Pharmacol; 2013 Jul; 84(1):62-70. PubMed ID: 23592516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis.
    Lee DH; Han DH; Nam KT; Park JS; Kim SH; Lee M; Kim G; Min BS; Cha BS; Lee YS; Sung SH; Jeong H; Ji HW; Lee MJ; Lee JS; Lee HY; Chun Y; Kim J; Komatsu M; Lee YH; Bae SH
    Free Radic Biol Med; 2016 Oct; 99():520-532. PubMed ID: 27634173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis.
    Okada K; Warabi E; Sugimoto H; Horie M; Tokushige K; Ueda T; Harada N; Taguchi K; Hashimoto E; Itoh K; Ishii T; Utsunomiya H; Yamamoto M; Shoda J
    J Gastroenterol; 2012 Aug; 47(8):924-35. PubMed ID: 22367278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physalin B ameliorates nonalcoholic steatohepatitis by stimulating autophagy and NRF2 activation mediated improvement in oxidative stress.
    Zhang MH; Li J; Zhu XY; Zhang YQ; Ye ST; Leng YR; Yang T; Zhang H; Kong LY
    Free Radic Biol Med; 2021 Feb; 164():1-12. PubMed ID: 33388433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2.
    Bathish B; Robertson H; Dillon JF; Dinkova-Kostova AT; Hayes JD
    Free Radic Biol Med; 2022 Aug; 188():221-261. PubMed ID: 35728768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
    Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
    JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomilin and its analogue obacunone alleviate NASH and hepatic fibrosis in mice via enhancing antioxidant and anti-inflammation capacity.
    Han Y; Luo L; Li H; Zhang L; Yan Y; Fang M; Yu J; Gao X; Liu Y; Huang C; Fan S
    Biofactors; 2023; 49(6):1189-1204. PubMed ID: 37401768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of NRF2 is correlated with the magnitude of inflammation and fibrosis in chronic liver disease.
    To K; Okada K; Watahiki T; Suzuki H; Tsuchiya K; Tokushige K; Yamamoto M; Ariizumi SI; Shoda J
    Cancer Med; 2023 Oct; 12(19):19423-19437. PubMed ID: 37732511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte-specific Keap1 deletion reduces liver steatosis but not inflammation during non-alcoholic steatohepatitis development.
    Ramadori P; Drescher H; Erschfeld S; Schumacher F; Berger C; Fragoulis A; Schenkel J; Kensler TW; Wruck CJ; Trautwein C; Kroy DC; Streetz KL
    Free Radic Biol Med; 2016 Feb; 91():114-26. PubMed ID: 26698665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placental extract ameliorates liver fibrosis in a methionine- and choline-deficient diet-induced mouse model of non-alcoholic steatohepatitis.
    Yamauchi A; Tone T; Toledo A; Igarashi K; Sugimoto K; Miyai H; Deng D; Nakamura J; Lim HS; Kaku T; Hirano E; Shindo T
    Biomed Res; 2020; 41(1):1-12. PubMed ID: 32092735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.
    Alshawsh MA; Alsalahi A; Alshehade SA; Saghir SAM; Ahmeda AF; Al Zarzour RH; Mahmoud AM
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis.
    Yang JJ; Tao H; Hu W; Liu LP; Shi KH; Deng ZY; Li J
    Cell Signal; 2014 Nov; 26(11):2381-9. PubMed ID: 25049078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
    Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
    JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH.
    Fernández-Ginés R; Encinar JA; Escoll M; Carnicero-Senabre D; Jiménez-Villegas J; García-Yagüe ÁJ; González-Rodríguez Á; Garcia-Martinez I; Valverde ÁM; Rojo AI; Cuadrado A
    Redox Biol; 2024 Feb; 69():103027. PubMed ID: 38184999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.